Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%